SOPHiA GENETICS (SOPH) investor relations material

Executive summary

• Revenue grew 27% year-over-year to $23.3 million in Q2 2026, driven by strong U.S. and Liquid Biopsy volume growth and BioPharma expansion.

• U.S. market was a primary growth driver, with 64% revenue and 60% volume growth year-over-year.

• Landed 24 new customers in Q2 and expanded within existing accounts, achieving net dollar retention of 117%.

• Signed major new partnerships, including two companion diagnostic (CDx) programs with AstraZeneca and a joint venture MoU with Memorial Sloan Kettering.

• Raised $57.5 million in an oversubscribed public offering, increasing cash and cash equivalents to $107.7 million.

Financial highlights

• Q2 2026 revenue was $23.3M, up 27% year-over-year; constant currency revenue growth was 25%.

• Platform analysis volume reached a record 115,000, up 22% year-over-year.

• Gross margin was 64.6% reported and 72.1% adjusted, both down from Q2 2025.

• Adjusted EBITDA loss improved to $8.8M from $12M, a 27% year-over-year improvement.

• Cash and cash equivalents rose to $107.7M at quarter-end, following the public offering.

Outlook and guidance

• Full-year 2026 revenue guidance raised to $94M-$96M (22%-24% growth).

• Full-year adjusted EBITDA loss guidance reaffirmed at $29M-$32M, improved from $41.5M in FY 2025.

• Expecting adjusted EBITDA breakeven by end of 2026 and positive adjusted EBITDA in H2 2027.

• CDx deals to impact growth primarily in 2027 and beyond.

• Precision medicine testing rates are increasing globally, with industry NGS CAGR forecasted at 7% from 2025 to 2026.